Aegerion Pharmaceuticals Inc.’s proposed settlement with the Department of Justice over its marketing of the homozygous familial hypercholesterolemia therapy Juxtapid includes one count related to violation of the FDA-mandated Risk Evaluation & Mitigation Strategy for the product.
The company’s May 12 announcement of a preliminary settlement with DoJ and the Securities & Exchange Commission does not get...